Ibrutinib, an FDA-approved, first-in-class orally administered BTK inhibitor that binds covalently to the C481 residue of BTK, has demonstrated impressive clinical activity in newly diagnosed and treatment-relapsed/refractory patients with CLL and many subtypes of NHL [4, 5]. The gene discussed is BTK; the disease is non-Hodgkin lymphoma.